Clinical Trials
Active studies & trials
Registry participants may be eligible for clinical trials testing new treatments for bronchiectasis and NTM. Explore active studies and learn how to participate.
Join the Registry
Your participation advances research
By joining our registry, you contribute to groundbreaking research that could lead to new treatments and better outcomes for thousands of patients.
Eligibility Criteria
Inclusion Criteria
- Adults over the age of 18
- Diagnosis of non-CF bronchiectasis
- Diagnosis of Nontuberculous Mycobacteria (NTM)
- Clinically stable at the time of enrolment
- Able to provide written informed consent
- No known allergy to study medications
Exclusion Criteria
- Under the age of 18
- Cystic fibrosis-related bronchiectasis
How to Enroll
Speak to Your Specialist
Ask your lung or infectious disease doctor whether your care site participates in CanBE-NTM—or could consider joining the registry.
Eligibility Review
Our team will review your medical history to confirm eligibility criteria.
Informed Consent
Review and sign the consent form after discussing the study with our team.
Begin Participation
Complete initial assessments and begin contributing to vital research.
To join, speak to your lung or infectious disease specialist and ask whether your care site is part of CanBE-NTM—or could consider joining the registry.
Questions?
Get in touch with our team
Have questions about eligibility, studies, or the registry? Our team is here to help. You can also speak to your doctor about referral to the registry.
Get Involved
Active studies & research collaborations
Registry participants may be eligible for clinical studies, airway-clearance research, and international bronchiectasis collaborations. Explore current opportunities and contact our team to learn more.
sOPEP Study
The sOPEP Study is evaluating tailored education and real-time feedback during OPEP therapy using a connected medical device that reports adherence through a mobile app. The study is being conducted at the University of Calgary and uses the Aerobika OPEP device.
Calgary, AB
Learn MoreAIRTIVITY Study
The AIRTIVITY Study is a Phase 3 randomized, placebo-controlled study evaluating BI 1291583 in people with bronchiectasis. Participants take either BI 1291583 or placebo once daily. The study includes site visits, phone calls, and smartphone symptom tracking to assess flare-ups, safety, and overall health.
Calgary, AB + multiple sites
Learn More